Division of Urologic Oncology, Department of Surgery, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
Hematol Oncol Clin North Am. 2011 Aug;25(4):765-91. doi: 10.1016/j.hoc.2011.06.002.
The standard of care for renal cell carcinoma (RCC) is surgical resection as a monotherapy or as part of a multimodal approach. A significant number of patients undergoing surgery for localized RCC experience recurrence, suggesting that there are some individuals in whom surgical excision is necessary but insufficient because of the presence of micrometastatic disease at diagnosis. This review summarizes current algorithms used to identify patients at high risk for disease recurrence following the surgical resection of RCC, the outcomes of contemporary adjuvant systemic therapy trials, and the rationale supporting the use of neoadjuvant therapy.
肾细胞癌 (RCC) 的标准治疗方法是手术切除作为单一疗法或作为多模式治疗的一部分。相当数量的接受局部 RCC 手术的患者出现复发，这表明由于在诊断时存在微转移疾病，有些患者需要手术切除，但这还不够。本综述总结了目前用于识别接受 RCC 手术后疾病复发风险高的患者的算法、当代辅助系统治疗试验的结果以及支持使用新辅助治疗的原理。
